TRX-518

TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR) . TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers[1].

Product Specifications

UNSPSC

12352203

Target

TNF Receptor

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.58

Smiles

[3H][R][X518]

Molecular Weight

(145.26 kDa)

References & Citations

[1]Zappasodi R, et al. Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial[J]. Cancer Research, 2017, 77 (13_Supplement) : CT018-CT018.